{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:39:48Z","timestamp":1775101188834,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T00:00:00Z","timestamp":1458172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal interstitial fibrosis is an important pathological feature of autosomal dominant polycystic kidney disease (ADPKD), which progressively develops to end\u2010stage renal disease (ESRD). It has been shown that apelin and transforming growth factor\u2010\u03b21 (TGF\u2010\u03b21) play important roles in the renal fibrosis process. The aim of the present study is to evaluate the relationship of these fibrosis markers and ADPKD. Forty\u2010five patients with ADPKD and 28 healthy controls were studied cross\u2010sectionally. Estimated glomerular filtration rate (eGFR), apelin, TGF\u2010\u03b21 were measured in all participants, using conventional methods. Apelin levels were lower (1.2\u2009\u00b1\u20090.9\u2009ng\/mL vs. 2.5\u2009\u00b1\u2009 1.3\u2009ng\/mL, <jats:italic>P\u2009&lt;<\/jats:italic>\u20090.001), while TGF\u2010\u03b21 levels were higher in the patient group according to healthy controls (466.5\u2009\u00b1\u2009 200.5\u2009ng\/L vs. 367.1\u2009\u00b1\u2009163.45\u2009ng\/L, <jats:italic>P\u2009=<\/jats:italic>\u20090.031), respectively. Apelin was negatively correlated with TGF\u2010\u03b21 and highly sensitive C\u2010reactive protein (hs\u2010CRP); and positively correlated with eGFR. In all subjects, eGFR was independently predicted by TGF\u2010\u03b21 and apelin. Apelin and TGF\u2010\u03b21 may be used as biomarkers of renal fibrosis that is an important pathological feature of ADPKD, which progressively develops to ESRD in ADPKD patients.<\/jats:p>","DOI":"10.1111\/1744-9987.12412","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T02:22:33Z","timestamp":1458354153000},"page":"517-522","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of Fibrosis Markers: Apelin and Transforming Growth Factor\u2010\u03b21 in Autosomal Dominant Polycystic Kidney Disease Patients"],"prefix":"10.1111","volume":"20","author":[{"given":"Derya","family":"Kocer","sequence":"first","affiliation":[{"name":"Department of Biochemistry Training and Research Hospital  Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Karakukcu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Training and Research Hospital  Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahir","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Erciyes University Medical Faculty  Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eray","family":"Eroglu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Erciyes University Medical Faculty  Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Kocyigit","sequence":"additional","affiliation":[{"name":"Department of Nephrology Erciyes University Medical Faculty  Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.27720"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307293290508"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90378-9"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311907"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2012.04.003"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345150"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.04.001"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1427"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.10.003"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00320.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69608"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0604"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2013.266411"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-014-1826-8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr389"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0754"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365513.2010.504281"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04140510"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92026-5"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.199"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2013.08.007"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00065.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339440"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-014-0045-4"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01341.2008"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000098430"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00086.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/1028415031000111273"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000106015.29070.E7"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2015.02.013"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs417"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-63"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353730"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1744-9987.12412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T09:11:06Z","timestamp":1695978666000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,17]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/1744-9987.12412"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12412","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,17]]}}}